PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
Azad, Abul Arshad, Maryam Generali, Daniele Feldinger, Katharina Gijsen, Merel Strina, Carla Cappelletti, Mariarosa Andreis, Daniele Leek, Russell Haider, Syed
Azad, Abul
Arshad, Maryam
Generali, Daniele
Feldinger, Katharina
Gijsen, Merel
Strina, Carla
Cappelletti, Mariarosa
Andreis, Daniele
Leek, Russell
Haider, Syed
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2024-11-24
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
No abstract available
Citation
Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C, Cappelletti M, Andreis D, Leek R, Haider S, Kellokumpu-Lehtinen PL, Roxanis I, Harris AL, Shaaban AM, Joensuu H, Kong A. PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer. Cancer Commun (Lond). 2025 Jan;45(1):68-73. doi: 10.1002/cac2.12632. Epub 2024 Nov 24.
Type
Correspondence